Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	44D0314742	05/10/2019
Name of Provider or Supplier	**Street Address, City, State**	
Ut Endocrinology/Lipoprotein Laboratory	956 Court Ave, Rm A223 & A229, Memphis, TN	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: The laboratory failed to maintain satisfactory performance for the glucose analyte for two consecutive proficiency testing (PT) events resulting in the first unsuccessful PT occurrence for the glucose analyte. (Refer to D2096)
D2096	ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is

	unsuccessful performance. This STANDARD is not met as evidenced by: Based on a desk review of the Centers for Medicare and Medicaid Casper Report 155 (CMS 155) and the laboratory's 2018 and 2019 proficiency testing (PT) records, the laboratory failed to maintain satisfactory performance for the glucose analyte, resulting in the first unsuccessful occurrence. The findings include: 1) Review of the CMS 155 revealed the following unsatisfactory scores for the glucose analyte: 2018 event 3 = 40%; 2019 event one = 40%. 2) Review of the laboratory's 2018 event 3 PT performance evaluation report revealed the following for the glucose analyte: Sample numbers CHM-11, CHM-13, and CHM-15 scored as unacceptable, resulting in a score of 40%. 3) Review of the laboratory's 2019 event 1 PT performance evaluation report revealed the following for the glucose analyte: Sample numbers CHM-03, CHM-04, and CHM-05 scored as unacceptable, resulting in a score of 40%, and the first unsuccessful PT occurrence.